Home › Research › Prevention trials
South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face‐to‐face and video communication platforms in mild cognitive impairment (SUPERBRAIN‐MEET): A randomized controlled trial
So Young Moon, Yoo Kyoung Park, Jee Hyang Jeong, Chang Hyung Hong, Jiwoo Jung, Hae Ri Na, Soo Hyun Cho, Hyun Sook Kim et al.. Alzheimer s & Dementia, 2025-01-22
Topic: Risk, prevention and care in population studies
The overall adherence rate to MI was 84.7%. The adjusted mean change from baseline at 24 weeks in the total scale index score of the repeatable battery for the assessment of neuropsychological status was 8.43 in the MI group and 4.26 in the control group (difference, 4.17; 95% confidence interval, 1.92-6.43; p < 0.001). MI showed significant beneficial effects on cognition in both apolipoprotein E (APOE) ε4 carriers and noncarriers. MI can exert beneficial effects on the cognition of patients with MCI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05023057 HIGHLIGHTS: Although the controls also demonstrated improved performance in cognition, multidomain interventions showed significantly greater benefits for cognition in MCI compared to the controls in a randomized controlled trial. Multidomain interventions improved depression and quality of life. Multidomain interventions significantly positively impacted cognition in both APOE ε4 carriers and noncarriers. Multidomain interventions may be more effective for amnestic than nonamnestic MCI.
Key findings
- The overall adherence rate to MI was 84.7%.
- The adjusted mean change from baseline at 24 weeks in the total scale index score of the repeatable battery for the assessment of neuropsychological status was 8.43 in the MI group and 4.26 in the control group (difference, 4.17; 95% confidence interval, 1.92-6.43; p < 0.001).
- MI showed significant beneficial effects on cognition in both apolipoprotein E (APOE) ε4 carriers and noncarriers.
- MI can exert beneficial effects on the cognition of patients with MCI.
- TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05023057 HIGHLIGHTS: Although the controls also demonstrated improved performance in cognition, multidomain interventions showed significantly greater benefits for cognition in MCI compared to the controls in a randomized controlled trial.
Why it matters
In this randomized trial of people with mild cognitive impairment, a multidomain intervention produced significantly greater cognitive improvement than the control group at 24 weeks, in both APOE ε4 carriers and noncarriers. It shows short-term cognitive benefit in MCI but does not demonstrate prevention or cure of Alzheimer's disease.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designrandomized controlled trial
- Effect size84.7%
- Evidence strengthHigh
How this study scored 66/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for sample size and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 3 / 7 | Cited 25 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 15.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 2 / 4 | Cited 25 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Seong Hye Choi: h-index 42 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Seoul National University: institution h-index 1,053 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 25 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39840755) |
| Free to read | 2 / 2 | Free to read |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Moon, S. Y., Park, Y. K., Jeong, J. H., Hong, C. H., Jung, J., Na, H. R., et al. (2025). South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face‐to‐face and video communication platforms in mild cognitive impairment (SUPERBRAIN‐MEET): A randomized controlled trial. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14517
Vancouver
Moon SY, Park YK, Jeong JH, Hong CH, Jung J, Na HR, et al. South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face‐to‐face and video communication platforms in mild cognitive impairment (SUPERBRAIN‐MEET): A randomized controlled trial. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14517. PMID: 39840755.
BibTeX
@article{moon2025-39840755,
author = {Moon, So Young and Park, Yoo Kyoung and Jeong, Jee Hyang and Hong, Chang Hyung and Jung, Jiwoo and Na, Hae Ri and Cho, Soo Hyun and Kim, Hyun Sook and others},
title = {{South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face‐to‐face and video communication platforms in mild cognitive impairment (SUPERBRAIN‐MEET): A randomized controlled trial}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.14517},
pmid = {39840755},
url = {https://doi.org/10.1002/alz.14517}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Prevention trials
Also tagged “cognitive-function”
1,118 studies in the library carry the topic tag “cognitive-function”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,118 tagged studies.